Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Disparities in ALL treatment toxicity

Taylor OA et al. Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-0939

Publish date:: September 13, 2018

Key clinical point: Hispanic patients with acute lymphoblastic leukemia had a higher risk of methotrexate toxicity compared with non-Hispanic whites.

Major finding: After researchers accounted for age, sex, ALL risk stratification, and other factors, the adjusted hazard ratio was 2.43 (95% CI, 1.06-5.58).

Study details: A prospective multicenter study of 280 patients with newly diagnosed ALL, nearly half of whom were Hispanic.

Disclosures: The research was supported by the National Institutes of Health and Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium, a St. Baldrick’s Foundation Consortium Research Grant. The study authors reported having no potential conflicts of interest.

Read the article here.

Citation:

Taylor OA et al. Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-0939.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Study: Complications from childhood ALL and its treatment are common, but can be managed,